“…In addition, Shi et al and Yang et al have shown that if AUS cases are forced into either lower or higher diagnostic risk categories, the latter results in diminished sensitivity for detecting thyroid neoplasms, with increased false-negative and false-positive rates, making thyroid FNA a less effective screening test. 31,47 Future Directions Although to our knowledge immunohistochemistry has only a very limited role in thyroid cytology, [48][49][50] molecular testing using markers such as BRAF, RET/PTC, RAS, and paired box gene (PAX)/peroxisome proliferator-activated receptor-c (PPAR-c) shows more promise for wider applicability. [51][52][53][54] A BRAF mutation or RET/PTC gene rearrangement has very high specificity for PTC.…”